Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Programmed death ligand 1 (PD-L1) on tumors interacts with PD-1 on CD8 T cells, suppressing antitumor immunity.
• Therapies targeting the PD-1/PD-L1 pathway restore T-cell activity and show promise in various cancers.
• Synovial sarcoma is an aggressive cancer where understanding immune evasion mechanisms is crucial.

Purpose of the Study:

• To investigate the expression levels and spatial distribution of PD-L1, PD-1, and CD8 in synovial sarcoma tissues.
• To determine the correlation between these markers and tumor stage (primary vs. metastatic).
• To explore the potential of these markers as predictors of response to PD-1 blockade therapy.

Main Methods:

• Retrospective analysis of 29 clinical synovial sarcoma samples.
• Quantitative immunohistochemistry to assess CD8+, PD-1+, and PD-L1+ cell densities.
• Multiplex immunofluorescence to evaluate colocalization and proximity of these immune markers within tumor tissues and invasive margins.

Main Results:

• Significantly higher densities of PD-L1, PD-1, and CD8 were observed in the invasive margins of metastatic tumors compared to primary tumors.
• Strong positive correlations were found between PD-L1, PD-1, and CD8 cell densities.
• PD-1 density in the invasive margin was associated with worse progression-free survival, and PD-1+ CD8 cells were found in proximity to PD-L1+ tumor cells.

Conclusions:

• The colocalization and increased density of PD-L1, PD-1, and CD8 in tumor margins are characteristic of metastatic synovial sarcoma.
• These findings suggest that PD-1 and PD-L1 expression patterns, particularly at the invasive margin, may serve as biomarkers for patient selection in PD-1 blockade therapy.
• Further preclinical investigation is warranted to validate these immune markers for guiding immunotherapy strategies in synovial sarcoma.